Cargando…
Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70
Hypertensive nephrosclerosis is the second most common cause of end-stage renal disease after diabetes. For years, hypertensive kidney disease has been focused on the afferent arterioles and glomeruli damage and the involvement of the renin angiotensin system (RAS). Nonetheless, in recent years, nov...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619557/ https://www.ncbi.nlm.nih.gov/pubmed/34831368 http://dx.doi.org/10.3390/cells10113146 |
_version_ | 1784605021656055808 |
---|---|
author | Costantino, Valeria Victoria Gil Lorenzo, Andrea Fernanda Bocanegra, Victoria Vallés, Patricia G. |
author_facet | Costantino, Valeria Victoria Gil Lorenzo, Andrea Fernanda Bocanegra, Victoria Vallés, Patricia G. |
author_sort | Costantino, Valeria Victoria |
collection | PubMed |
description | Hypertensive nephrosclerosis is the second most common cause of end-stage renal disease after diabetes. For years, hypertensive kidney disease has been focused on the afferent arterioles and glomeruli damage and the involvement of the renin angiotensin system (RAS). Nonetheless, in recent years, novel evidence has demonstrated that persistent high blood pressure injures tubular cells, leading to epithelial–mesenchymal transition (EMT) and tubulointerstitial fibrosis. Injury primarily determined at the glomerular level by hypertension causes changes in post-glomerular peritubular capillaries that in turn induce endothelial damage and hypoxia. Microvasculature dysfunction, by inducing hypoxic environment, triggers inflammation, EMT with epithelial cells dedifferentiation and fibrosis. Hypertensive kidney disease also includes podocyte effacement and loss, leading to disruption of the filtration barrier. This review highlights the molecular mechanisms and histologic aspects involved in the pathophysiology of hypertensive kidney disease incorporating knowledge about EMT and tubulointerstitial fibrosis. The role of the Hsp70 chaperone on the angiotensin II–induced EMT after angiotensin II type 1 receptor (AT(1)R) blockage, as a possible molecular target for therapeutic strategy against hypertensive renal damage is discussed. |
format | Online Article Text |
id | pubmed-8619557 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86195572021-11-27 Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70 Costantino, Valeria Victoria Gil Lorenzo, Andrea Fernanda Bocanegra, Victoria Vallés, Patricia G. Cells Review Hypertensive nephrosclerosis is the second most common cause of end-stage renal disease after diabetes. For years, hypertensive kidney disease has been focused on the afferent arterioles and glomeruli damage and the involvement of the renin angiotensin system (RAS). Nonetheless, in recent years, novel evidence has demonstrated that persistent high blood pressure injures tubular cells, leading to epithelial–mesenchymal transition (EMT) and tubulointerstitial fibrosis. Injury primarily determined at the glomerular level by hypertension causes changes in post-glomerular peritubular capillaries that in turn induce endothelial damage and hypoxia. Microvasculature dysfunction, by inducing hypoxic environment, triggers inflammation, EMT with epithelial cells dedifferentiation and fibrosis. Hypertensive kidney disease also includes podocyte effacement and loss, leading to disruption of the filtration barrier. This review highlights the molecular mechanisms and histologic aspects involved in the pathophysiology of hypertensive kidney disease incorporating knowledge about EMT and tubulointerstitial fibrosis. The role of the Hsp70 chaperone on the angiotensin II–induced EMT after angiotensin II type 1 receptor (AT(1)R) blockage, as a possible molecular target for therapeutic strategy against hypertensive renal damage is discussed. MDPI 2021-11-12 /pmc/articles/PMC8619557/ /pubmed/34831368 http://dx.doi.org/10.3390/cells10113146 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Costantino, Valeria Victoria Gil Lorenzo, Andrea Fernanda Bocanegra, Victoria Vallés, Patricia G. Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70 |
title | Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70 |
title_full | Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70 |
title_fullStr | Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70 |
title_full_unstemmed | Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70 |
title_short | Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70 |
title_sort | molecular mechanisms of hypertensive nephropathy: renoprotective effect of losartan through hsp70 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619557/ https://www.ncbi.nlm.nih.gov/pubmed/34831368 http://dx.doi.org/10.3390/cells10113146 |
work_keys_str_mv | AT costantinovaleriavictoria molecularmechanismsofhypertensivenephropathyrenoprotectiveeffectoflosartanthroughhsp70 AT gillorenzoandreafernanda molecularmechanismsofhypertensivenephropathyrenoprotectiveeffectoflosartanthroughhsp70 AT bocanegravictoria molecularmechanismsofhypertensivenephropathyrenoprotectiveeffectoflosartanthroughhsp70 AT vallespatriciag molecularmechanismsofhypertensivenephropathyrenoprotectiveeffectoflosartanthroughhsp70 |